

CANADIAN CANCER TRIALS GROUP

GENITOURINARY

DISEASE SITE COMMITTEE MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: WREN

SATURDAY APRIL 30TH, 2016: 10:00 AM – 3:45 PM

CHAIRS: K. CHI & N. FLESHNER

SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO

STUDY COORDINATOR: ALEXANDER MONTENEGRO

(03:45 PM – 04:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with Canadian Cancer Trials Group.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

10:00 am WELCOME

K. Chi

- CCSRI Grant
- CCTG Strategic Plan

CCTG Lead OPEN TRIALS

10:10 am BL.12 Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel
in Second Line Metastatic Urothelial Carcinoma

K. Sridhar

CCTG InterGroup OPEN TRIALS

10:15 am BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a
Standard versus an Extended Pelvic Lymphadenectomy Performed
at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer

W. Kassouf

10:20 am PR.13/RADICALS/MRC PR.10
Radiotherapy and Androgen Deprivation In Combination After Local Surgery

C. Catton

10:25 am PRC.4/Alliance A031201 Phase III Enzalutamide + Abiraterone in castration
resistant metastatic prostate cancer

K. Chi

continued on next page ...

10:30 am PR.17/ANZUP 1304- ENZAMET Phase III testosterone suppression with or without Enzalutamide in first line metastatic prostate cancer S. North

CCTG Lead CLOSED TRIALS

10:35 am IND.209 Reolysin in Combination with Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic CRPC B. Eigl

10:45 am PR.15 HDR Brachytherapy in Intermediate Risk CaP E. Vigneault/ A. Loblaw

CCTG InterGroup CLOSED TRIALS

10:50 am REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC M. Jewett/ L. Wood

10:55 am PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only K. Chi

CCTG Approved TRIALS

11:00 am PR.18/TOPARP: A Phase II Double-Blind Placebo Controlled Trial of Olaparib 400mg BID Vs Placebo in Unselected Patients With Advanced Castration Resistant Prostate Cancer Who Have Not Received Taxane-Based Chemotherapy. K. Chi

11:10 am REC.3/PAPMET A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib and Savolitinib versus Sunitinib in Metastatic Papillary Renal Carcinoma. D. Heng

11:20 am PR.19: A randomized phase II trial evaluating treatment outcome, acute and long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as monotherapy in localized prostate cancer. L. Hathout

11:30 am IND.232: A Phase II Study of Durvalumab (Medi4736) with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer S. Hotte

11:35 am OPEN CUOG/CURC TRIALS

Synergy	K.Chi
EORTC Cytoreductive	M. Jewett
FIT	L. Klotz
ProstVac	N.Fleshner
Hypothermia RCC	I. Cagiannos
MAC trial	A.Loblaw/N.Fleshner

12:00 pm LUNCH

continued on next page ...

1:30 pm Plenary Presentation: Challenges and Opportunities for Immunotherapy in Prostate Cancer.
Dr James Gulley [biography](#)

2:10 pm DOG REPORTS/NEW PROPOSALS/GU DIRECTIONS

Localized Prostate Cancer
Advanced Prostate Cancer
Bladder
Kidney
Testes
IND
Correlative Studies

A. Loblaw
F. Saad/K. Chi
S. North/W. Kassouf/A. So
A. Kapoor/D. Heng
P. Chung/ C. Kollmannsberger
S. Hotte
D. Berman

3:45 pm Meeting Adjourned

3:45 PM – 4:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED